Novo Nordisk has appointed Maziar Mike Doustdar as its new CEO, signaling a shift towards a more aggressive and risk-tolerant strategy to compete with rival Eli Lilly in the lucrative U.S. weight-loss drug market. This change in leadership comes after a significant $70 billion share rout for Novo Nordisk, triggered by a profit warning and concerns about losing ground in the obesity drug race. Doustdar's predecessor, Lars Fruergaard Jorgensen, was removed in May after the company's shares slumped since mid-last year, losing over 20% on the day of the profit warning.
Doustdar is reportedly willing to take new risks, exemplified by his pursuit of an unconventional deal structure worth about $10 billion, five times what his predecessor would have paid. This aggressive stance is aimed at making Novo more competitive and faster to market. Analysts and investors, including Erik Berg-Johnsen of Storebrand Asset Management, have welcomed this new "sense of urgency" from the company.
However, Doustdar faces skeptical investors, concerned about his lack of U.S. experience, which is crucial for turning around sales in Novo's top market. The company's 2025 sales outlook was cut from 13-21% to 8-14% due to lower growth expectations in the U.S. for both Wegovy and Ozempic. The stock plunge has also been attributed to rising competition, with Eli Lilly's Mounjaro and Zepbound reportedly outperforming Ozempic and Wegovy in gaining U.S. GLP-1 prescriptions. Furthermore, the U.S. patent on Novo Nordisk's key ingredient semaglutide is set to expire in 2032, increasing the pressure to develop "second-generation" products before generic alternatives flood the market.
Compounding Novo Nordisk's challenges, the company initially faced temporary product shortages in U.S. pharmacies, leading to compounders selling lower-priced versions. While availability has improved, the entry of copycat rivals and the robust performance of Eli Lilly's competitive drugs have put significant pressure on Novo's market position. The company's market capitalization, once Europe's most valuable, has seen substantial fluctuations, and investors are looking for a clear strategy to address these competitive and market-related hurdles.
